“Gas Station Heroin”: States Move to Ban Tianeptine as Doctors Warn of Growing Overdose Risk
Tianeptine, nicknamed “gas station heroin,” is an unapproved antidepressant in the U.S., sold unregulated online and in stores; at high doses it produces opioid-like effects that can cause addiction, respiratory depression, overdose and nationwide death.
Key takeaways
- State actions: Fourteen U.S. states now classify tianeptine as a Schedule I controlled substance; Connecticut recently added a ban and expanded its schedule.
- Regulatory warning: The FDA says tianeptine is unapproved and can produce opioid-like euphoria, addiction, respiratory depression and death.
- Marketing risk: Products are sold as supplements or mood aids under brand names like Tianaa, ZaZa, Neptune’s Fix and TD Red and are often flavored or mislabeled.
- Clinical challenge: Poison centers and emergency departments report rising exposures, severe illnesses and ICU cases; routine drug screens often miss tianeptine.
What is tianeptine and why is it called “gas station heroin”?
Tianeptine was developed as an antidepressant and is prescribed at low, monitored doses in some countries. In the U.S., however, the FDA has never approved it for medical use or as a dietary supplement. Instead, it has shown up in unregulated products sold at convenience stores, gas stations, vape shops and online—often at doses far above therapeutic ranges. Those high-dose formulations can act on opioid receptors and produce strong opioid-like effects, which is why clinicians and public health officials have dubbed it “gas station heroin.” (NCBI; Mayo Clinic.)
How the drug works at different doses
At low, clinically supervised doses used in some countries, tianeptine affects serotonin reuptake and functions as an antidepressant. At much higher doses—the kind commonly found in illicit retail products—it stimulates the mu-opioid receptor, producing euphoria and respiratory depression. Some reports suggest the opioid effect at high doses may be more potent than morphine. (NCBI; FDA.)
Health risks and reported harms
Misuse of tianeptine is linked to numerous serious harms, including:
- Central nervous system and respiratory depression, severe sedation and coma. (FDA.)
- Cardiovascular effects such as hypertension and arrhythmias; seizures have been reported in clusters. (NJ Health alert.)
- Withdrawal syndromes resembling opioid withdrawal: intense cravings, chills, diarrhea, muscle pain and depression. (Mayo Clinic.)
- Increased danger when combined with alcohol, benzodiazepines or opioids; co-use is associated with more severe outcomes. (NJ Health alert.)
Clinical note: Routine toxicology screens often miss tianeptine, complicating diagnosis and treatment in emergency settings. Poison control centers have documented rising calls and clusters of severe cases—including investigations tied to products like ZaZa Red and Neptune’s Elixir. (VCU Health; NJ Health alert.)
Sales, marketing and the “candy” problem
Investigators say many tianeptine products are marketed with false or misleading claims—pitched as mood enhancers, pain relievers or cognitive aids. They appear in pill, powder, salt and liquid forms and are sometimes flavored to appeal to younger users. Connecticut officials criticized the candy-like flavors and convenience-store placement that make these products especially dangerous for people with substance-use disorders and for youth. (FDA.)
Legal and regulatory responses
State-level action has accelerated: fourteen states list tianeptine as a Schedule I controlled substance, and several others are moving to restrict sales or labeling. Connecticut’s recent action added tianeptine alongside kratom, 7-hydroxymitragynine, bromazolam, flubromazolam, nitazenes and phenibut to its controlled-substance schedule. Lawmakers in Virginia, North Carolina and elsewhere have passed similar measures. (VCU Health; NJ Health alert.)
At the federal level, legislators have reintroduced bills aimed at banning dangerous marketing. Representative Frank Pallone and Senator Dick Durbin reintroduced legislation to prohibit misleading marketing of tianeptine products. (Pallone press release.)
Voices from medicine and public health
FDA leadership has publicly warned about tianeptine’s risks to youth and the broader public, urging awareness and action. Clinicians treating overdoses call for swifter measures and national scheduling. In the words of one emergency clinician:
“The drug has never been approved as a dietary supplement in the U.S. While low doses increase serotonin activity, higher doses stimulate mu-opioid receptors and can be lethal—leading to respiratory arrest similar to heroin.” — Dr. Robert Schwaner, vice chair, Stony Brook Emergency Medicine.
Clinicians urge: consider tianeptine in unexplained opioid-like overdoses, remember routine screens may not detect it, and consult toxicology or poison control for management guidance. (FDA; VCU Health.)
International approaches: some regulation, more warnings
Outside the U.S., tianeptine is used in some countries as a prescribed antidepressant at controlled doses. Still, regulators in multiple nations have tightened rules, updated labels, restricted prescribing or required stronger warnings about addiction risk. International cooperation on labeling and online sales enforcement could help limit unregulated products. (NCBI; Mayo Clinic.)
What consumers and clinicians should do now
- Suspected exposure or overdose: contact local poison control or emergency services immediately (for example, New Jersey poison control: 1‑800‑222‑1222). (NJ Health alert.)
- Help for substance-use problems: call the SAMHSA National Helpline at 1‑800‑662‑HELP (4357) or visit the SAMHSA helpline for free, confidential support 24/7.
- For clinicians: include tianeptine in the differential for unexplained opioid-like overdoses, consult poison control and consider specialized testing where available. (FDA.)
Implications for The World
Economic: Unregulated online sales and cross-border shipping allow products to reach countries without strong controls, burdening health systems and emergency services. Targeting online marketplaces and sellers could reduce supply and limit spikes in emergency care. (FDA.)
Political: Governments must choose between tighter regulation, public education or criminal penalties. Nations that prescribe tianeptine face a balancing act between medical access and protecting the public.
Social and cultural: Candy-like flavors, convenience-store placement and misleading marketing increase youth exposure; public health campaigns targeting parents, schools and retailers are critical. (Mayo Clinic.)
Practical: Health systems should update toxicology panels where possible, train emergency clinicians on recognition and withdrawal management, and enhance poison-center surveillance. (VCU Health.)
Resources and help
If you or someone you know is struggling with substance use, the SAMHSA National Helpline provides free, confidential support 24/7. For suspected exposures, contact your local poison control center or emergency services immediately. (Example: 1‑800‑222‑1222 in New Jersey.) (NJ Health alert.)
Reporting and sources
This report draws on federal advisories, state health alerts, clinical commentary and peer-reviewed summaries. Key sources include the FDA alert, a Mayo Clinic overview, a national-science summary at NCBI, state alerts from New Jersey (NJ Health alert), clinical guidance from VCU Health, and recent legislative action (Pallone press release).
